Crisprbits secures $250,000 in pre-seed funding round

• ByStartupStory     |    February 14, 2023

Bengaluru’s CrisprBits has secured $250,000 in pre-seed funding from VJ Group in the US. The funds will support product development, team expansion, and research and development efforts. CrisprBits, founded in 2020 by Dr Vijay Chandru, Sunil Arora, Dr Rajeev Kohli, Bharat Jobanputra, and Aditya Sarda, aims to create affordable healthcare solutions in diagnostics and gene editing for all Indians.

 The firm intends to expand its CRISPR-based diagnostics platform to point-of-care pathogen detection and the identification of antimicrobial resistance genes linked to hospital-acquired infections.

CrisprBits has recently created OmiCrisp, a CRISPR-based test that can detect whether a person is infected with the Omicron or non-Omicron variant of SARS-CoV2. The development of this test was made possible with the help of C-CAMP-InDx, an initiative supported by the Department of Biotechnology, Govt of India.

According to Sunil Arora, the company’s CEO and co-founder, this new investment will hasten the firm’s growth and enable the development of additional high-quality healthcare solutions in diagnostics and gene editing.

Dr. Vijay Chandru, the Chief Scientific Officer and Co-Founder of CrisprBits, has stated that the firm is employing cutting-edge CRISPR gene editing technology to offer superior life sciences solutions to all Indians. With the recent publication of the OmiCrisp manuscript, a CRISPR-based test for SARS-CoV2, the company is highlighting its commitment to infectious disease surveillance and one health. 

Additionally, CrisprBits is preparing to launch the “PATHCRISP” point of care platform, which will provide accessible solutions to everyone. The company is also investigating new therapeutic strategies in gene editing for oncology, cardio-vascular applications, and even industrial biotechnology applications.

Follow Startup Story